We are live on ! Find out more
ECYT

Endocyte, Inc. Common Stock
ECYT

Delisted

ECYT was delisted on the 20th of December, 2018.

98 hedge funds and large institutions have $109M invested in Endocyte, Inc. Common Stock in 2015 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 34 increasing their positions, 28 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

21% more repeat investments, than reductions

Existing positions increased: 34 | Existing positions reduced: 28

3% more capital invested

Capital invested by funds: $106M → $109M (+$2.7M)

7% less first-time investments, than exits

New positions opened: 13 | Existing positions closed: 14

2% less funds holding

Funds holding: 10098 (-2)

25% less call options, than puts

Call options by funds: $1.49M | Put options by funds: $1.98M

Holders
98
Holders Change
-2
Holders Change %
-2%
% of All Funds
2.61%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
13
Increased
34
Reduced
28
Closed
14
Calls
$1.49M
Puts
$1.98M
Net Calls
-$490K
Net Calls Change
+$239K
Name Holding Trade Value Shares
Change
Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$30.8M -$474K -82,192 -2%
BFA
2
BlackRock Fund Advisors
California
$9.83M +$101K +17,524 +1%
Vanguard Group
3
Vanguard Group
Pennsylvania
$6.74M +$322K +55,842 +5%
HCMT
4
Highland Capital Management (Texas)
Texas
$6.26M +$5M +866,176 +651%
PA
5
Pinnacle Associates
New York
$6.24M +$39.8K +6,890 +0.7%
Millennium Management
6
Millennium Management
New York
$5.07M -$472K -81,710 -9%
State Street
7
State Street
Massachusetts
$4.64M +$885K +153,369 +26%
NI
8
Numeric Investors
Massachusetts
$3.48M -$1.5M -259,205 -32%
Northern Trust
9
Northern Trust
Illinois
$2.46M -$8.88K -1,538 -0.4%
BIT
10
BlackRock Institutional Trust
California
$2.42M -$11.7K -2,029 -0.5%
Renaissance Technologies
11
Renaissance Technologies
New York
$2.37M -$914K -158,305 -29%
Bank of New York Mellon
12
Bank of New York Mellon
New York
$1.47M +$102K +17,637 +8%
OAM
13
Oxford Asset Management
United Kingdom
$1.43M +$1.32M +228,375 New
CRC
14
Curi RMB Capital
Illinois
$1.38M +$5.77K +1,000 +0.5%
Geode Capital Management
15
Geode Capital Management
Massachusetts
$1.27M +$22K +3,807 +2%
AQR Capital Management
16
AQR Capital Management
Connecticut
$1.22M -$104K -18,100 -9%
BAMS
17
Bellevue Asset Management (Switzerland)
Switzerland
$1.19M +$1.1M +190,215 New
Deutsche Bank
18
Deutsche Bank
Germany
$1.19M -$774K -134,163 -41%
Susquehanna International Group
19
Susquehanna International Group
Pennsylvania
$1.17M -$921K -159,581 -46%
California Public Employees Retirement System
20
California Public Employees Retirement System
California
$884K
TCIM
21
TIAA CREF Investment Management
New York
$882K +$39.6K +6,863 +5%
Charles Schwab
22
Charles Schwab
California
$871K +$272K +47,170 +51%
BCM
23
Bridgeway Capital Management
Texas
$782K
MERSOM
24
Municipal Employees' Retirement System of Michigan
Michigan
$736K
BIM
25
BlackRock Investment Management
Delaware
$685K +$2.78K +482 +0.4%

ECYT Hedge Fund Activity: Q1 2015 in Review

98 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Endocyte, Inc. Common Stock (ECYT) for Q1 2015, worth a combined $109M — up 2.5% from $106M a quarter earlier.

Sellers outnumbered buyers: 14 funds closed out of ECYT and 13 opened new positions — a net loss of 1 holder — while 28 trimmed existing stakes and 34 added.

The largest buyer was Highland Capital Management (Texas), adding an estimated $5M. The largest seller was Numeric Investors, cutting an estimated $1.5M.

  • 98 institutional investors held Endocyte, Inc. Common Stock (ECYT) as of Q1 2015, down from 100 in Q4 2014.
  • Funds reported $109M of Endocyte, Inc. Common Stock stock for Q1 2015, up 2.5% quarter-over-quarter.
  • 13 funds opened new Endocyte, Inc. Common Stock positions in Q1 2015 and 14 closed out, a net change of -1 holder.
  • The largest Endocyte, Inc. Common Stock buyer in Q1 2015 was Highland Capital Management (Texas), an estimated $5M added.
  • The largest Endocyte, Inc. Common Stock seller in Q1 2015 was Numeric Investors, an estimated $1.5M sold.

Based on aggregated 13F filings for Q1 2015.